
Claims

1. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis in a patient in need thereof, wherein Formula I is represented by:



,

and wherein the patient is orally administered a compound of Formula I at a daily amount of about 90 mg or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I or a pharmaceutically acceptable salt thereof is administered twice per day, and wherein

(i) the patient has consumed food within 1 hour prior to receiving said compound;

(ii) the administering is performed at a time the patient consumes a meal; or

(iii) the patient consumes a meal within 1 hour after receiving said compound.


2. The use of claim 1, wherein the medicament is to be orally administered to the patient having a compound of Formula I at a daily amount of 90 mg or a pharmaceutically acceptable salt thereof.

3. The use of claim 1, wherein the medicament is to be orally administered twice per day as a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of about 45 mg or a pharmaceutically acceptable salt thereof.

4. The use of claim 1, wherein the medicament is to be orally administered twice per day as a unit dosage, wherein each unit dosage contains a compound of Formula I in an amount of 45 mg or a pharmaceutically acceptable salt thereof.

5. Use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of multiple sclerosis, wherein the medicament is to be orally administered to

a patient in need thereof twice daily as a unit dosage containing the compound in an amount of about 45 mg or a pharmaceutically acceptable salt thereof, wherein the patient consumes a meal within 1 hour after the administration, and Formula I is represented by:



.

6. The use of claim 5, wherein the unit dosage is to be administered to the patient in the form of one or more unit formulations containing the compound of Formula I or a pharmaceutically acceptable salt thereof.

7. The use of claim 6, wherein the unit formulation(s) are in the form of a tablet or capsule.

8. The use of any one of claims 5-7, wherein the unit dosage contains about 45 mg of compound of Formula I.

9. The use of any one of claims 5-7, wherein the unit dosage contains 45 mg of compound of Formula I.

10. The use of any one of claims 5-9, wherein the medicament is to be administered at the time the patient consumes a meal.

11. The use of any one of claims 5-10, wherein there is at least 8 hours between administration of a first unit dosage and a second unit dosage to the patient on the same day.

12. The compound for use of any one of claims 5-11, wherein a first unit dosage is administered to the patient in the morning, and a second unit dosage is administered to the patient in the evening.

13. The compound for use of any one of claims 5-9, wherein a first unit dosage is administered to the patient at the time the patient consumes a breakfast meal in the morning, and a second unit dosage is administered to the patient at the time the patient consumes a dinner meal in the evening.

14. The compound for use of any one of claims 5-13, wherein the patient receives the unit dosage two times per day for a duration of at least 2 weeks.

15. The compound for use of any one of claims 5-13, wherein the patient receives the unit dosage two times per day for a duration of at least 1 month.

16. The compound for use of any one of claims 5-13, wherein the patient receives the unit dosage two times per day for a duration of at least 6 months.

17. The compound for use of any one of claims 1-8, wherein the multiple sclerosis is relapsing multiple sclerosis, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, or progressive-relapsing multiple sclerosis.

18. The compound for use of any one of claims 1-17, wherein the multiple sclerosis is relapsing multiple sclerosis.

19. The compound for use of any one of claims 1-18, wherein the patient is an adult human.

20. The compound for use of any one of claims 1-19, wherein the patient is in a fed state when the compound of Formula I or pharmaceutically acceptable salt thereof is administered to the patient.